Understanding how the immune system detects and fights cancer cells
CD91 and cancer immunosurveillance
This study is looking at how our immune system can spot and get rid of early cancer cells before they turn into tumors, focusing on certain proteins and cells that help boost our body's natural defenses, with the hope of creating better treatments that use our own immune system to fight cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10746105 on NIH RePORTER |
What this research studies
This research investigates how the immune system identifies and eliminates early-stage cancer cells before they develop into tumors. It focuses on the role of heat shock proteins and a specific receptor, CD91, on dendritic cells, which are crucial for activating T cells and natural killer (NK) cells. By exploring the molecular mechanisms behind these processes, the research aims to enhance the immune response against tumors, particularly when cancer antigens are present in low amounts. The findings could lead to improved cancer immunotherapies that harness the body's own immune system.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with early-stage cancers or those at high risk of developing cancer.
Not a fit: Patients with advanced-stage cancers or those who do not have a functioning immune system may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that boost the immune system's ability to fight tumors.
How similar studies have performed: Previous research has shown promise in using heat shock proteins to enhance immune responses against tumors, indicating that this approach may be effective.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Binder, Robert J — University of Pittsburgh at Pittsburgh
- Study coordinator: Binder, Robert J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.